Updates are available Correction dated 2023-01-12
Click to view Correction: https://doi.org/10.1007/s10286-022-00917-7
-
Authors
Goldstein, David S. https://orcid.org/0000-0002-5709-9940
Sharabi, Yehonatan
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (Z1A NS003034)
- License Information
-
More Information
Article History
Received: 15 October 2022
Accepted: 27 November 2022
First Online: 12 December 2022
Change Date: 12 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10286-022-00917-7
Declarations
:
: D.S.G. reports no disclosures. Yehonatan Sharabi reports no disclosures. This is not an industry-sponsored study. The authors declare that they have no conflict of interest.
: Participants in this study gave written informed consent to participate in IRB-approved intramural NINDS protocols. Consent for the PDRisk study was in two forms: electronic at a protocol-specific, IRB-approved website and in writing at the time of evaluation at the NIH Clinical Center. The study is listed in ClinicalTrials.gov (study NCT00775853). For comparison purposes, physiological data were culled from an ongoing database under an IRB-approved secondary research protocol (NIH Clinical Protocol 000490). Data were reviewed from all participants with PD + OH, PD without OH (PD No OH), or PAF or who were healthy volunteers (HVs) studied at the NIH Clinical Center between 1991 and 2022.
